Trial Profile
A open label, observational, multicenter, prospective, post marketing surveillance study (PMS) to evaluate safety and efficacy of sulbactomax (FDC of Ceftriaxone + Sulbactam) in patients with various bacterial infections
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Ceftriaxone/sulbactam (Primary)
- Indications Bacterial meningitis; Bone and joint infections; Enteric fever; Gonorrhoea; Otitis media; Postoperative infections; Respiratory tract disorders; Sepsis; Skin and soft tissue infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors Venus Remedies
- 14 May 2012 New trial record